ReviewWorld journal of cardiology2025
Role of polymorphisms and microRNA levels in predicting cardiovascular events in patients with acute myocardial infarction.
Review in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs in Cardiovascular Diseases: Molecular Networks of Cellular Homeostasis, Inflammation, and Pathological Remodeling.International journal of molecular sciences · 2026Review
- MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia.BMC pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction (AMI) remains a leading global cause of morbidity and mortality, with high risk of recurrent adverse cardiovascular events. Conventional diagnostic markers often lack the sensitivity needed for early detection and prognostic stratification. Recent advances highlight the role of microRNAs (miRNAs) and their genetic polymorphisms in regulating inflammation, fibrosis, and endothelial function in atherosclerotic disease. This review summarizes evidence on circulating miRNA expression and miRNA-related single nucleotide polymorphisms as biomarkers in AMI. Literature from PubMed, Scopus, and Web of Science was evaluated, focusing on pathways involving NF-κB, interleukin-1 receptor/toll-like receptors, and JAK/STAT signaling. Circulating miRNAs such as miR-150, miR-208, miR-26a, and miR-483-5p demonstrate strong diagnostic accuracy, while polymorphisms, particularly rs2910164 in miR-146a, are consistently associated with AMI susceptibility and adverse outcomes. These findings suggest that miRNAs and their variants may serve as non-invasive tools for diagnosis and risk prediction, supporting future integration into precision cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.